AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04123067
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo daily for three subsequent days, initiated within 12h of stroke symptom onset
Trial: NCT00009828
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00441090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
Trial: NCT01121042
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily oral capsule matched to active study medication. Made form 100% lactose powder
Trial: NCT03238300
Drug: Placebo Oral Capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine-matched placebo tablet two pills twice daily. Participants will undergo MRI (including magnetic resonance imaging and functional MRI during an alcohol cue reactivity task) at baseline, after 10 days of N-Acetylcysteine and after 10 days of placebo.
Trial: NCT03030222
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin matching placebo
Trial: NCT04869176
Drug: Caffeine Citrate 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine in the form of suspension was given to the newborns.
Trial: NCT04280406
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: azithromycin 500mg one hour before implant placement
Trial: NCT04280406
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical placebo one hour before implant placement
Trial: NCT02161458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additionally, 30 cognitively normal adults aged 60-85 will receive a placebo; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., placebo) administration.
Trial: NCT02624830
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Arm description.
Trial: NCT00286845
Drug: Standard Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: physician determined
Trial: NCT03051503
Drug: The Transdermal Therapeutic System-Fentanyl (TTS-F)
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (TTS-F) group (n=30) 50ug/h patch, placed 12 hours preoperatively
Trial: NCT02410278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT01856062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo with similar appearance to dexamethasone will be given with a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
Trial: NCT01315002
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch
Trial: NCT03228394
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV
Trial: NCT00407888
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00407888
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT04058353
Drug: ELX/TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablet for oral administration.
Trial: NCT04058353
Drug: TEZ/IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) tablet for oral administration.
Trial: NCT04536272
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of heparin with a target of 2-2.5 or 1.5-2.0 times baseline aPTT during ECLS.
Trial: NCT04536272
Drug: LMWH
RxNorm normalized name: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of LMWH guided by weight and renal function during ECLS.
Trial: NCT01423955
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
Trial: NCT02889653
Drug: Any oral antithrombotics (antiplatelets or anticoagulants)
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02470546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1000mg twice a day
Trial: NCT01760096
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoids0.25mg/kg every day(prednisone)
Trial: NCT04102579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-active dosage form
Trial: NCT03419364
Drug: nicotinamide
RxNorm normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 gm nicotinamide given orally in 3 divided doses: 1000 mg in morning and evening, 500 mg at noon/midday
Trial: NCT02406092
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered as per standard local practice.
Trial: NCT02406092
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be administered as per standard local practice.
Trial: NCT00951132
Drug: rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg tablets, once daily in three months
Trial: NCT00951132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, once daily, three months
Trial: NCT01218009
Drug: Placebo Spiromax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as a dry-powder inhaled orally using the Spiromax inhaler. During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.
Trial: NCT03491540
Drug: Oral Gentamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral gentamycin:~Gentamycin 80 mg, 4 per day, on day -2 and day -1; Liquid forms in individual vials
Trial: NCT04024072
Drug: Azopt 1% Ophthalmic Suspension
RxNorm normalized name: Azopt 1% Ophthalmic Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product
Trial: NCT02604615
Drug: Capecitabine(Aibin)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine(Aibin):625mg/m2,bid d1-5; q1w, po,5 or 10 weeks in total
Trial: NCT01525602
Drug: PLX3397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLX3397 tablets, 200mg
Trial: NCT03491540
Drug: Oral Placebo Gentamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for oral gentamycin :~Same presentation as oral gentamycin x4 per day on day -2 and day -1
Trial: NCT00871689
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg over 1 hour intravenously (IV) on days -7 and -6.
Trial: NCT00238030
Drug: L-thryoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mcg/kg iv or 2 mcg/kg po at time of enrollment
Trial: NCT02520219
Drug: GDP
RxNorm normalized name: GDPase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GDP is a a combination therapy,repeated every 21 days. GEM(gemcitabine)1000mg/m2,ivgtt,30,d1、8; DXM(dexamethasone),40mg/d,p.o,d1-4; DDP(cis-platinum),75mg/m2,ivgtt,\>1h,d1; or DDP25 mg/m2,ivgtt,\>1h,d1-3.
Trial: NCT00238030
Drug: iv thryoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thyroxine 2 mcg/kg iv
Trial: NCT02873559
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone supplemented in 5 months
Trial: NCT02878616
Drug: LFG316
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LFG316 single dose
Trial: NCT04665154
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose i.v. and s.c.
Trial: NCT01291212
Drug: Testosterone and FSHr-LHr
RxNorm normalized name: testosterone and estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75U of LHr added to FSHr ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
Trial: NCT01291212
Drug: testosterone and FSHr alone
RxNorm normalized name: testosterone and estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FSHr alone used in ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
Trial: NCT01253213
Drug: BR55
RxNorm normalized name: Band-Aid Ourtone BR55 Bandages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One to two bolus (2nd bolus optional) of BR55 per patient
Trial: NCT02644590
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Detailed in arm description
Trial: NCT00678743
Drug: Omacor + simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omacor 4 grams/day plus simvastatin 80 mg/day. Simvastatin dose adjusted at Investigator discretion after week 6.
Trial: NCT02238288
Drug: lidocaine and epinephrine
RxNorm normalized name: epinephrine / lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2%
Trial: NCT01344070
Drug: one of the 15 drugs listed below
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single, oral, immediate-release, non-combinational innovator formulation
Trial: NCT01344070
Drug: one of the 15 drugs listed below
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single, oral, immediate-release, non-combinational generic formulation a
Trial: NCT01344070
Drug: one of the 15 drugs listed below
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single, oral, immediate-release, non-combinational generic formulation b
Trial: NCT01344070
Drug: one of the 15 drugs listed below
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single, oral, immediate-release, non-combinational generic formulation c
Trial: NCT01533662
Drug: patients receiving saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients more than 60 years receiving 100micrograms of saline infusion
Trial: NCT00879983
Drug: azithromycin (Zithromax)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. a single dose of azithromycin ER 2g~2. 3-day regimen of azithromycin tablet 500mg
Trial: NCT01928420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects with Alzheimer's Disease placebo comparator
Trial: NCT04225793
Drug: Eziklen®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Eziclen solution should be taken in the one-time use regimen in morning before procedure.~Consumption of the full volume of the Eziklen® solution of the preparation and the additional amount of water or a clear liquid should be completed at least 2 hours and no later than 4 hours before the procedure.
Trial: NCT00455143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo given prior to surgery and continued for 24 hours postoperatively
Trial: NCT00879983
Drug: azithromycin (Zithromax)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. 3-day regimen of azithromycin tablet 500mg~2. a single dose of azithromycin ER 2g
Trial: NCT02867722
Drug: aminolevulinic acid HCl
RxNorm normalized name: aminolevulinic acid HCl
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug will be administered to consented patients
Trial: NCT01376245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT00091962
Drug: Pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommendations to patients' PCP for medication to treat depression
Trial: NCT02101229
Drug: Insulin, Asp(B28)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the insulin dose is calculated by the Diabeloop algorithm and then administered to the patient
Trial: NCT02250105
Drug: ARI-3037MO
RxNorm normalized name: OVIS ARIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid lowering
Trial: NCT02250105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive
Trial: NCT01143688
Drug: placebo inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00702728
Drug: isotonic saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive 1 ml/Kg/hr of intravenous saline solution for a minimum of 12 hours prior to catheterization. Hydration will continue to occur during the catheterization, and for a minimum of 12 hours post catheterization.
Trial: NCT02820441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01957163
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The matching placebo DPI identical in appearance to the inhaler containing active study medication.
Trial: NCT03196869
Drug: induction Chrono-chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group:docetaxel,cisplatin,5-FU
Trial: NCT03196869
Drug: induction Routine-chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control group:docetaxel,cisplatin,5-FU
Trial: NCT00111670
Drug: DPP-IV Inhibitor
RxNorm normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses po bid or qd
Trial: NCT00111670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po bid or qd
Trial: NCT03687190
Drug: conventional medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants without Tai chi training still received routine conventional medicine
Trial: NCT04232514
Drug: HEC74647
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered HEC74647 200 mg orally once daily in fed state
Trial: NCT04232514
Drug: HEC110114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered HEC110114 800 mg orally once daily in fed state
Trial: NCT03243006
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of placebo
Trial: NCT03294330
Drug: IC-Green KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluorescence lymphangiography with the use of IC-Green
Trial: NCT00380250
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000520
Drug: immunoglobulins, intravenous
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00648128
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose 500 mg immediate-release oral tablet
Trial: NCT00648128
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single-dose 500 mg immediate-release oral dose'
Trial: NCT01262456
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02486289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBMI Placebo
Trial: NCT04466137
Drug: rhG-CSF/PEG-rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhG-CSF 5μg/kg/day, s.c. from day 3 to day 14 or until neutrophils recover to exceed 5.0×10\^9 cells/L, whichever comes first, in the first cycle. Patient can still continue rhG-CSF 5μg/kg/day, or covert to PEG-rhG-CSF 6mg/Cycle in the following 2-4 cycle. 21 day one cycles.
Trial: NCT02235246
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline will be administrated during 10 min before anesethetic induction in patients undergoing endoscopic submucosal dissection.
Trial: NCT02466958
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an inactive drug
Trial: NCT03332303
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Cream
Trial: NCT03985891
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folfox
Trial: NCT04334265
Drug: Anluohuaxian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6g each time, twice a day
Trial: NCT02782702
Drug: Botulism Toxin Treatment
RxNorm normalized name: Botulism toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of 50 UI of botulism toxin for treated zone
Trial: NCT01919203
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The starting dose of remifentanil is 0.5μg/kg and a step size is 0.05μg/kg. If LMA insertion is successful or failed in previous patient, an decrement or increment of 0.05μg/kg remifentanil is injected to next patient, respectively.
Trial: NCT03156738
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single IV dose of placebo
Trial: NCT01287130
Drug: AZD6244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally once or twice a day depending on dose level.On days 1, 8, 15 and 22. Repeat every 28 days
Trial: NCT00729209
Drug: ARRY-371797, p38 inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, single schedule
Trial: NCT00729209
Drug: Placebo; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT03865004
Drug: Dexketoprofen plus Morphine
RxNorm normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 75 mg Dexketoprofen plus 0,1 mg/kg morphine were performed simultanously
Trial: NCT01012349
Drug: Association: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet in an episody of headache
Trial: NCT01012349
Drug: Aspirin - Bayer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet in an episody of headache (Aspirin 500mg)
Trial: NCT00122642
Drug: placebo-lock
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
Trial: NCT00480701
Drug: [123I]-IBVM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be asked to undergo an injection of 123-I IBVM followed by up to three approximately thirty minute SPECT scans during the next 24 hours.
Trial: NCT03022201
Drug: Placebo DA-9701
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00307749
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily for 24 weeks
Trial: NCT04798313
Drug: Prolia®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects would receive a single 60mg (1 mL) of Prolia® through subcutaneous injection, on the first day of treatment.
Trial: NCT03574597
Drug: Placebo (semaglutide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.
Trial: NCT00765232
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
Trial: NCT00765232
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
Trial: NCT00038051
Drug: Hum-195/rGel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting Dose = 3 mg/m\^2 twice weekly for 2 weeks.
Trial: NCT00057551
Drug: Medication Only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antidepressant medication
Trial: NCT00960180
Drug: MR1817
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00960180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01319266
Drug: Hydrocodone Bitartrate extended-release tablet
RxNorm normalized name: hydrocodone bitartrate Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone bitartrate extended-release oral tablet will be administered at a dose of 45 mg and dosed one time on Day 1. Subjects will also be dosed with naltrexone hydrochloride to block opioid effects.
Trial: NCT00045305
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antimetabolite
Trial: NCT00045305
Drug: Photopheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psoralens